{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:57:03Z","timestamp":1777510623541,"version":"3.51.4"},"reference-count":33,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lipidjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.jacl.2018.04.006","type":"journal-article","created":{"date-parts":[[2018,4,21]],"date-time":"2018-04-21T13:36:52Z","timestamp":1524317812000},"page":"857-862","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Variations in time to benefit among clinical trials of cholesterol-lowering drugs"],"prefix":"10.1016","volume":"12","author":[{"given":"Philip J.","family":"Barter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David D.","family":"Waters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2018.04.006_bib1","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.jacc.2005.03.077","article-title":"Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial","volume":"46","author":"Ray","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2018.04.006_bib2","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","article-title":"The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels","volume":"335","author":"Sacks","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2018.04.006_bib3","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1056\/NEJM199908053410604","article-title":"Gemfibrozil for secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol","volume":"341","author":"Rubins","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2018.04.006_bib4","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1056\/NEJMoa1600176","article-title":"Cholesterol lowering in intermediate-risk persons without cardiovascular disease","volume":"374","author":"Yusuf","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2018.04.006_bib5","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s40266-013-0095-7","article-title":"Rationalizing prescribing for older patients with multimorbidity; considering time to benefit","volume":"30","author":"Holmes","year":"2013","journal-title":"Drugs Aging"},{"key":"10.1016\/j.jacl.2018.04.006_bib6","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)","volume":"344","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2018.04.006_bib7","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2018.04.006_bib8","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1001\/jama.285.13.1711","article-title":"Effect of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study: a randomized controlled trial","volume":"285","author":"Schwartz","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2018.04.006_bib9","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJM199511163332001","article-title":"Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia","volume":"333","author":"Shepherd","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2018.04.006_bib10","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","article-title":"Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicenter randomised placebo-controlled trial","volume":"364","author":"Colhoun","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2018.04.006_bib11","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2018.04.006_bib12","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","article-title":"Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS\/TexCAPS","volume":"279","author":"Downs","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2018.04.006_bib13","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(03)12948-0","volume":"361","author":"Sever","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2018.04.006_bib14","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199811053391902","article-title":"Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels","volume":"339","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2018.04.006_bib15","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/S0140-6736(02)11600-X","article-title":"Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial","volume":"360","author":"Shepherd","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2018.04.006_bib16","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S0140-6736(06)69472-5","article-title":"Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial","volume":"368","author":"Nakamura","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2018.04.006_bib17","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomized placebo-controlled trial","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2018.04.006_bib18","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus moderate lipid lowering with statins in acute coronary syndromes","volume":"350","author":"Cannon","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2018.04.006_bib19","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa050461","article-title":"Intensive lipid lowering with atorvastatin in patients with stable coronary disease","volume":"352","author":"LaRosa","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2018.04.006_bib20","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1001\/jama.294.19.2437","article-title":"High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction. The IDEAL study: a randomized controlled trial","volume":"294","author":"Pedersen","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2018.04.006_bib21","first-page":"35","article-title":"The Lipid Research Clinics Coronary Primary Prevention Trial results","volume":"251","year":"1984","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2018.04.006_bib22","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1056\/NEJM198711123172001","article-title":"Helsinki Heart Study: Primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia","volume":"317","author":"Frick","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2018.04.006_bib23","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy for acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2018.04.006_bib24","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2018.04.006_bib25","author":"Steg"},{"key":"10.1016\/j.jacl.2018.04.006_bib26","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1056\/NEJMoa1706444","article-title":"Effects of anacetrapib in patients with atherosclerotic vascular disease","volume":"377","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2018.04.006_bib27","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","article-title":"Interpretation of the evidence for the efficacy and safety of statin therapy","volume":"388","author":"Collins","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2018.04.006_bib28","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1161\/01.CIR.99.25.3215","article-title":"Cholesterol lowering: should it continue to be the last thing we do?","volume":"99","author":"Waters","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2018.04.006_bib29","doi-asserted-by":"crossref","first-page":"9337","DOI":"10.1074\/jbc.M513000200","article-title":"Active metabolite of atorvastatin inhibits membrane cholesterol domain formation by an antioxidant mechanism","volume":"281","author":"Mason","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jacl.2018.04.006_bib30","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/FJC.0b013e318294998d","article-title":"Atorvastatin active metabolite inhibits oxidative modification of small dense low-density lipoprotein","volume":"62","author":"Jacob","year":"2013","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.jacl.2018.04.006_bib31","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/FJC.0000000000000379","article-title":"Eicosapentaenoic acid inhibits oxidation of apoB-containing lipoprotein particles of different size in\u00a0vitro when administered alone or in combination with atorvastatin active metabolite compared with other triglyceride-lowering agents","volume":"68","author":"Mason","year":"2016","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.jacl.2018.04.006_bib32","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1161\/CIRCULATIONAHA.115.019014","article-title":"Long-term safety and efficacy of lowering low-density lipoprotein cholesterol with statin therapy. 20-year follow-up of West of Scotland coronary prevention study","volume":"133","author":"Ford","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2018.04.006_bib33","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.cjca.2017.07.001","article-title":"The evolution of myocardial infarction: when the truths we hold to be self-evident no longer have evidence","volume":"33","author":"Waters","year":"2017","journal-title":"Can J Cardiol"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287418302046?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287418302046?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,7,25]],"date-time":"2018-07-25T03:38:51Z","timestamp":1532489931000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287418302046"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["S1933287418302046"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2018.04.006","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Variations in time to benefit among clinical trials of cholesterol-lowering drugs","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2018.04.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 National Lipid Association. All rights reserved.","name":"copyright","label":"Copyright"}]}}